New Evidence Points To Role For Free Radicals In Alzheimer's Disease

December 04, 1998

In a new study by University of Pennsylvania Medical Center researchers, free-radical activity was found to be roughly doubled in the frontal and temporal lobes of the brains of people who had died of Alzheimer's disease when compared to the same regions of normal brains.

Additionally, the frontal and temporal lobes were the only parts of the brains where the levels of two recently identified biochemical markers of free-radical tissue damage were seen to be elevated. This is an important observation because these two areas of the brain, critical for memory and intellectual function, are the ones most affected by the disease. A report on the new findings appears in the December issue of the FASEB Journal.

"The strength of what we found was that, firstly, these markers were elevated only in the affected parts of the brains of people who died of Alzheimer's disease," says Garret A. FitzGerald, MD, chairman of the department pharmacology and senior author on the report. "And, secondly, the markers were not elevated in the same parts of the brains of people who died of other causes. This suggests that what we're looking at are sensitive, quantitative indicators of disease activity."

The most abundant of the two markers was also found to be significantly elevated in the cerebrospinal fluid, or CSF. The importance of this finding is that the CSF is a relatively accessible body fluid, so that extensions of the current work into living patients presumed to have Alzheimer's disease will be possible. Indeed, such studies have already begun at Penn. Likely to emerge from these investigations will be more accurate methods for disease diagnosis, improved assessments of drugs against the disease, and a clearer overall picture of the disease process.

For example, results from epidemiological studies suggest that anti-inflammatory drugs (e.g., ibuprofen) and antioxidant compounds (e.g., vitamin E) both offer some protection against Alzheimer's disease. Although inflammation is linked to oxidant stress and its associated tissue damage, it would be useful to know whether and to what degree these processes, independently or in concert, drive the progression of the disease. And which class of drugs -- anti-inflammatories or antioxidants -- offers the greatest potential benefit to patients?

"People debate the initiating cause of Alzheimer's disease, but there's general agreement that there is an inflammatory component, and inflammation is associated with oxidant stress," says FitzGerald. "So, it becomes relevant whether drug targets associated with inflammation will represent distinct or overlapping targets from those involved in oxidation. In other words, if we give a patient an anti-inflammatory, should we expect any additional benefit from an antioxidant vitamin or drug? Currently, we don't know the answer. Our ongoing studies should begin to address that question."

The innovative measurement technique used in all of these experiments was developed in FitzGerald's laboratory in collaboration with Joshua Rokach, PhD, a chemist at the Florida Institute of Technology and coauthor on the current report. It assesses the levels in body fluids or tissues of certain biochemicals called isoprostanes. These isoprostanes are stable byproducts of free-radical catalyzed damage to lipids, or fatty molecules, found throughout the body, and they serve as quantitative markers for that damage.

The lead author on the study is Domenico Pratico, MD, an assistant professor of pharmacology at Penn. Coauthors on the study, in addition to Rokach, include Virginia M.-Y. Lee, PhD, and John Q. Trojanowski, MD, PhD, both professors of pathology and laboratory medicine at Penn. Funding for the work was provided by the National Institutes of Health.

The University of Pennsylvania Medical Center's sponsored research and training ranks third in the United States based on grant support from the National Institutes of Health, the primary funder of biomedical research and training in the nation -- $175 million in federal fiscal year 1997. In addition, for the third consecutive year, the institution posted the highest annual growth in these areas -- 17.6 percent -- of the top ten U.S. academic medical centers. News releases from the University of Pennsylvania Medical Center are available to reporters by direct e-mail, fax, or U.S. mail, upon request. They are also posted electronically to the medical center's home page (http://www.med.upenn.edu), to EurekAlert! (http://www.eurekalert.org), an Internet resource sponsored by the American Association for the Advancement of Science, and to the electronic news services Newswise (http://www.newswise.com).
-end-


University of Pennsylvania School of Medicine

Related Inflammation Articles from Brightsurf:

3D printed stents that treat inflammation
POSTECH Professor Dong-Woo Cho's research team develops bioink-loaded esophageal stents for treating radiation esophagitis.

New cause of inflammation in people with HIV identified
A new study led by researchers at Boston Medical Center examined what factors could be contributing to this inflammation, and they identified the inability to control HIV RNA production from existing HIV DNA as a potential key driver of inflammation.

Maltreatment tied to higher inflammation in girls
New research by a University of Georgia scientist reveals that girls who are maltreated show higher levels of inflammation at an early age than boys who are maltreated or children who have not experienced abuse.

A protein that controls inflammation
A study by the research team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) has unraveled a critical molecular mechanism behind autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.

Inflammation in the brain linked to several forms of dementia
Inflammation in the brain may be more widely implicated in dementias than was previously thought, suggests new research from the University of Cambridge.

Social isolation could cause physical inflammation
Social isolation could be associated with increased inflammation in the body new research from the University of Surrey and Brunel University London has found.

Hydrogels control inflammation to help healing
Researchers test a sampling of synthetic, biocompatible hydrogels to see how tuning them influences the body's inflammatory response.

Why beta-blockers cause skin inflammation
Beta-blockers are often used to treat high blood pressure and other cardiovascular diseases.

The 'inflammation' of opioid use
New research correlates inflammation in the brain and gut to negative emotional state during opioid withdrawal.

Using a common anticonvulsant to counteract inflammation
The interaction between a chromosomal protein called HMGB1 and a cellular receptor called RAGE is known to trigger inflammation.

Read More: Inflammation News and Inflammation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.